Page last updated: 2024-10-25

deferoxamine and Syndrome

deferoxamine has been researched along with Syndrome in 15 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Syndrome: A characteristic symptom complex.

Research Excerpts

ExcerptRelevanceReference
" Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage."6.53Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016)
"Evidence has emerged over the last several years indicating that aluminum accumulation in patients with chronic renal failure can cause certain forms of renal osteodystrophy, in particular osteomalacia and an aplastic lesion."4.77Aluminum and renal osteodystrophy. ( Coburn, JW; Nebeker, HG, 1986)
" It is also the second case report of a Pearson patient suffering from severe iron overload and liver disease that responded to therapy with deferoxamine."3.74Pearson syndrome in an infant heterozygous for C282Y allele of HFE gene. ( Augoustides-Savvopoulou, P; Farmaki, E; Karatza, E; Kefala-Agoropoulou, K; Lazaridou, A; Roilides, E; Tsantali, H; Tsiouris, J, 2007)
" Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage."2.53Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016)
" In the United States, deferiprone has been approved for three times daily dosing since 2011 and has recently gained approval for twice-daily administration."1.91An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes. ( Badawy, SM; Shah, A; Shah, R, 2023)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19909 (60.00)18.7374
1990's1 (6.67)18.2507
2000's2 (13.33)29.6817
2010's2 (13.33)24.3611
2020's1 (6.67)2.80

Authors

AuthorsStudies
Shah, R1
Shah, A1
Badawy, SM1
Kontoghiorghe, CN1
Kontoghiorghes, GJ1
Taher, AT1
Porter, JB1
Kattamis, A1
Viprakasit, V1
Cappellini, MD1
Kefala-Agoropoulou, K1
Roilides, E1
Lazaridou, A1
Karatza, E1
Farmaki, E1
Tsantali, H1
Augoustides-Savvopoulou, P1
Tsiouris, J1
Bottomley, SS1
Ambruso, DR1
Mahony, BS1
Githens, JH1
Rhoades, ED1
Chekanov, VS1
Nikolaychik, V1
O'Brien, RT1
Graziano, JH1
Arnold, H1
Wehinger, H1
Deus, B1
Löhr, GW1
Forget, BG1
Nathan, DG1
Cacciola, E1
Nebeker, HG1
Coburn, JW1
Rovelli, E1
Luciani, L1
Pagani, C1
Albonico, C1
Colleoni, N1
D'Amico, G1
Vadász, G1

Reviews

6 reviews available for deferoxamine and Syndrome

ArticleYear
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents;

2016
Sideroblastic anaemia.
    Clinics in haematology, 1982, Volume: 11, Issue:2

    Topics: 5-Aminolevulinate Synthetase; Adult; Anemia, Sideroblastic; Blood Transfusion; Bone Marrow; Chloramp

1982
Iron overload: clinical and pathologic aspects in pediatrics.
    Seminars in hematology, 1977, Volume: 14, Issue:1

    Topics: Abnormalities, Multiple; Adolescent; Adult; Ascorbic Acid Deficiency; Bloodletting; Child; Child, Pr

1977
Iron metabolism and chelation therapy in hemosiderosis.
    Current topics in hematology, 1978, Volume: 1

    Topics: Ascorbic Acid; Blood Transfusion; Chelating Agents; Deferoxamine; Diet; Gentisates; Hemochromatosis;

1978
Thalassemia.
    Annual review of medicine, 1975, Volume: 26

    Topics: Blood Transfusion; Bone Marrow Examination; Deferoxamine; Diagnosis, Differential; Erythrocyte Count

1975
Aluminum and renal osteodystrophy.
    Annual review of medicine, 1986, Volume: 37

    Topics: 24,25-Dihydroxyvitamin D 3; Aluminum; Animals; Bone and Bones; Calcitriol; Caseins; Chronic Kidney D

1986

Other Studies

9 other studies available for deferoxamine and Syndrome

ArticleYear
An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes.
    Expert review of hematology, 2023, Volume: 16, Issue:2

    Topics: Benzoates; Blood Transfusion; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overloa

2023
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Benzoates; Chelation Therapy; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron Chelating

2016
Pearson syndrome in an infant heterozygous for C282Y allele of HFE gene.
    Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:6

    Topics: Anemia, Sideroblastic; Deferoxamine; Fatal Outcome; Female; Hemochromatosis; Hemochromatosis Protein

2007
Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    The American journal of pediatric hematology/oncology, 1982,Summer, Volume: 4, Issue:2

    Topics: Administration, Oral; Anemia, Aplastic; Ascorbic Acid; Blood Transfusion; Child; Chromosome Aberrati

1982
Iron contributes to endothelial dysfunction in acute ischemic syndromes.
    Circulation, 2002, Jan-29, Volume: 105, Issue:4

    Topics: Acute Disease; Coronary Circulation; Coronary Disease; Deferoxamine; Endothelial Growth Factors; End

2002
[Controlled desferrioxamine treatment of congenital anaemia and transfusion siderosis (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1978, Aug-04, Volume: 103, Issue:31

    Topics: Adolescent; Anemia, Aplastic; Child; Deferoxamine; Erythrocytes, Abnormal; Humans; Iron; Male; Sider

1978
[Dyserythropoietic syndromes: incidence, diagnosis, therapy].
    Recenti progressi in medicina, 1990, Volume: 81, Issue:10

    Topics: Anemia, Dyserythropoietic, Congenital; Anemia, Refractory; Anemia, Sideroblastic; Deferoxamine; Diag

1990
Correlation between serum aluminum concentration and signs of encephalopathy in a large population of patients dialyzed with aluminum-free fluids.
    Clinical nephrology, 1988, Volume: 29, Issue:6

    Topics: Aluminum; Brain Diseases; Deferoxamine; Electroencephalography; Female; Humans; Male; Middle Aged; N

1988
[A case of Diamond-Blackfan anemia: Experiences of 10-year follow-up study].
    MMW, Munchener medizinische Wochenschrift, 1974, Nov-22, Volume: 116, Issue:47

    Topics: Adolescent; Anemia, Aplastic; Biopsy; Blood Transfusion; Child; Child, Preschool; Deferoxamine; Eryt

1974